OneSkin cosmetic cream reduces senescent cells in skin

21-Jul-2020

Key points from article :

OneSkin began life validating effectiveness of skincare products. Developed its own skin aging clock based on skin-specific epigenetic DNA markers. Screened a synthetic library for antimicrobial peptides. From an initial list of 200 AMPs, the team looked at the four compounds . Generated 800 novel sequences led to the lead compounds, OS-1 and OS-2. These two peptides had the most potential for tackling senescence (by 25-50%) caused by aging UV light and genotoxic stress. Inability to reduce the growth of some bacteria strains indicate that the compounds are not anti-microbial. OneSkin is topically applied and classed as a cosmetic. Safety studies performed to assess skin irritation, corrosion and sensitisation. OneSkin’s patented compound OS-1 tackles senescent skin cells. Product launches in October. OS-1 has also extended the median lifespan of C. Elegans by over 20%. Carolina Reis Oliveria, CEO, confirmed company has pre-seed funding from Indiebio & SOSV and seed round funding from 2Future.